Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas

American Journal of Ophthalmology

Volumn 136, Issue 1, 2003, Pages 194-196

  Girmens, Jean François ^a   Erginay, Ali ^a   Massin, Pascale ^a   Scigalla, Paul ^b   Gaudric, Alain ^a   Richard, Stéphane ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b SUGEN INC   (United States)

^c BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; DEXAMETHASONE; RANITIDINE; SEMAXANIB; VASCULOTROPIN INHIBITOR;

ADULT; ARTICLE; BEAM THERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; CRYOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEMANGIOBLASTOMA; HUMAN; HYPERSENSITIVITY; LASER COAGULATION; MULTICENTER STUDY; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; POLYCYTHEMIA; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; RETINA MACULA CYSTOID EDEMA; RETINA TUMOR; STATISTICAL SIGNIFICANCE; THICKNESS; TREATMENT OUTCOME; TUMOR VOLUME; VISUAL ACUITY; VON HIPPEL LINDAU DISEASE;

EID: 0038015673     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(03)00101-6     Document Type: Article

References (6)

1. Richard S., Croisille L., Yvart J., et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with antivascular endothelial growth factor receptor therapy. Blood. 99:2002;3851-3853.
2. Dollfus H., Massin P., Taupin P., et al. Retinal hemangioblastoma in von Hippel-Lindau disease a clinical and molecular study . Invest Ophthalmol Vis Sci. 43:2002;3067-3074.
3. Los M., Aarsman C.J., Terpstra L., et al. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann Oncol. 8:1997;1015-1022.
4. Mendel D.B., Laird A.D., Smolich B.D., et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent. Anticancer Drug Des. 15:2000;29-41.
5. Harris A.L. Von Hippel-Lindau syndrome target for antivascular endothelial growth factor (VEGF) receptor therapy . Oncologist. 5:(Suppl 1):2000;32-36.
6. Aiello L.P., George D.J., Cahill M.T., et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU 5416. Ophthalmology. 109:2002;1745-1751.